Effects of Testosterone and Progressive Resistance Exercise in Healthy, Highly Functioning Older Men with Low-normal Testosterone Levels
Overview
Authors
Affiliations
Context: Aging in men is associated with reduced testosterone (T) levels and physiological changes leading to frailty, but the benefits of T supplementation are inconclusive.
Objective: We studied the effects of T supplementation with and without progressive resistance training (PRT) on functional performance, strength, and body composition.
Design, Setting, And Participants: We recruited 167 generally healthy community-dwelling older men (66 ± 5 years) with low-normal baseline total T levels (200-350 ng/dL).
Intervention: Subjects were randomized to placebo or transdermal T gel [2 doses targeting either a lower (400-550 ng/dL) or higher (600-1000 ng/dL) T range] and to either PRT or no exercise for 12 months.
Main Outcome Measure: The primary outcome was functional performance, whereas secondary outcomes were strength and body composition.
Results: A total of 143 men completed the study. At 12 months, total T was 528 ± 287 ng/dL in subjects receiving any T and 287 ± 65 ng/dL in the placebo group. In the PRT group, function and strength were not different between T- and placebo-treated subjects, despite greater improvements in fat mass (P = .04) and fat-free mass (P = .01) with T. In the non-PRT group, T did not improve function but improved fat mass (P = .005), fat-free mass (P = .03), and upper body strength (P = .03) compared with placebo. There were fewer cardiovascular events in the T-treated groups compared with placebo.
Conclusions: T supplementation was well tolerated and improved body composition but had no effect on functional performance. T supplementation improved upper body strength only in nonexercisers compared with placebo.
Otzel D, Nichols L, Conover C, Marangi S, Kura J, Iannaccone D Front Neurol. 2024; 15():1479264.
PMID: 39722695 PMC: 11668665. DOI: 10.3389/fneur.2024.1479264.
Cruickshank M, Hudson J, Hernandez R, Aceves-Martins M, Quinton R, Gillies K Health Technol Assess. 2024; 28(43):1-210.
PMID: 39248210 PMC: 11404359. DOI: 10.3310/JRYT3981.
Midttun M, Overgaard K, Zerahn B, Pedersen M, Rashid A, Ostergren P J Cachexia Sarcopenia Muscle. 2024; 15(4):1451-1462.
PMID: 38890228 PMC: 11294024. DOI: 10.1002/jcsm.13498.
Green D, Chasland L, Yeap B, Naylor L Sports Med Open. 2024; 10(1):30.
PMID: 38563849 PMC: 10987448. DOI: 10.1186/s40798-024-00703-x.
Frailty in the cardiac intensive care unit: assessment and impact.
Moumneh M, Jamil Y, Kalra K, Ijaz N, Campbell G, Kochar A Eur Heart J Acute Cardiovasc Care. 2024; 13(6):506-514.
PMID: 38525951 PMC: 11214587. DOI: 10.1093/ehjacc/zuae039.